Lilly, Boehringer score FDA backing for Lantus copy, but patent fight awaits

Eli Lilly ($LLY) nabbed tentative FDA approval for its knockoff version of Sanofi's diabetes blockbuster Lantus, but the company won't be able to sell its copycat--dubbed Basaglar--for at least 30 months because of a patent fight with Sanofi ($SNY). Lilly and its partner Boehringer Ingelheim have to duke it out in patent court with the French drugmaker, which sued for infringement earlier this year. Release | Report

Suggested Articles

Not even two months into a probe of officials accused of taking Novartis bribes, Greece's parliament is handing off the investigation.

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.